OPKO HEALTH, INC.
OPKOPKO Health, Inc. is a medical test and medication company focused on diagnostics and pharmaceuticals. The company is a publicly traded company on NASDAQ and TASE under the symbol "OPK".
Drugs in Pipeline
18
Phase 3 Programs
6
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 1 past
No catalysts found.
How OPK's past catalysts played out
Somatropin
Pediatric Growth Hormone Deficiency
MOD-4023
Pediatric Growth Hormone Deficiency
CTAP101 30 μg capsules
Chronic Kidney Disease
Genotropin
Growth Hormone Deficiency
CTAP101 Capsules
Chronic Kidney Disease
Cohort 1 CTAP101 Capsules- 60µg
Chronic Kidney Disease
CTA018 cream
Psoriasis
Rayaldee
COVID-19
MDX2003
Lymphoma
MDX2004
Advanced Tumors
MDX2001
Biliary Tract Cancer
LY2944876
Diabetes Mellitus, Type 2
CTA018 Injection
Chronic Kidney Disease
TT223 with Metformin and/or TZD
Diabetes Mellitus, Type 2
OPK-88003
Type 2 Diabetes Mellitus
ELND005 (scyllo-inositol)
Alzheimer's Disease
ELND005
Alzheimer's Disease
bevasiranib
Diabetic Macular Edema
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Somatropin | Phase 3 | Pediatric Growth Hormone Deficiency | - | - |
MOD-4023 | Phase 3 | Pediatric Growth Hormone Deficiency | - | - |
CTAP101 30 μg capsules | Phase 3 | Chronic Kidney Disease | - | - |
Genotropin | Phase 3 | Growth Hormone Deficiency | - | - |
CTAP101 Capsules | Phase 3 | Chronic Kidney Disease | - | - |
Cohort 1 CTAP101 Capsules- 60µg | Phase 3 | Chronic Kidney Disease | - | - |
CTA018 cream | Phase 2 | Psoriasis | - | - |
Rayaldee | Phase 2 | COVID-19 | - | - |
MDX2003 | Phase 2 | Lymphoma | - | - |
MDX2004 | Phase 2 | Advanced Tumors | - | - |
MDX2001 | Phase 2 | Biliary Tract Cancer | - | - |
LY2944876 | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
CTA018 Injection | Phase 2 | Chronic Kidney Disease | - | - |
TT223 with Metformin and/or TZD | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
OPK-88003 | Phase 2 | Type 2 Diabetes Mellitus | - | - |
ELND005 (scyllo-inositol) | Phase 2 | Alzheimer's Disease | - | - |
ELND005 | Phase 2 | Alzheimer's Disease | - | - |
bevasiranib | Phase 2 | Diabetic Macular Edema | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in OPKO HEALTH, INC.'s drug pipeline?→
CatalystAlert tracks 18 drug candidates in OPKO HEALTH, INC.'s (OPK) pipeline across Phase 3, Phase 2. Its lead program is Somatropin (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is OPKO HEALTH, INC.'s next FDA catalyst?→
OPKO HEALTH, INC.'s (OPK) next tracked catalyst is a Earnings expected July 30, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track OPK biotech catalysts?→
Add OPK to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow OPKO HEALTH, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.